87 recruiting, 55 completed, 49 unknown, 38 not yet recruiting. 130 Phase 2, 33 Phase 1, 30 Not applicable, 24 Phase 3, 5 Phase 4.
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer Biospecimen Collection, Computed Tomography, Immunotherapy - Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 2 | Not yet recruiting | NRG Oncology | 138 | 2026-12-18 | 2026-09-23 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. FMT combined with chemotherapy plus immunotherapy, Chemotherapy+Immunotherapy - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 40 | 2026-11-01 | 2026-10-02 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| Primary Radiotherapy In MEtastatic Lung Cancer Radiotherapy followed by chemotherapy, Standard of Care (SOC) - Carcinoma, Non-Small-Cell Lung (NSCLC) | Phase 3 | Recruiting | Trans Tasman Radiation Oncology Group | 420 | 2026-10-30 | 2026-10-23 |
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 164 | 2026-10-14 | 2026-10-19 |
| Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer Personalized ultrafractionated stereotactic adaptive radiotherapy, Immunotherapy, Target Therapy - Colo-rectal Cancer | Phase 2 | Not yet recruiting | West China Hospital | 32 | 2026-10-09 | 2026-10-29 |
| Oral Immunotherapy for Children With Peanut Allergy Oral immunotherapy with peanut - Peanut Allergic Subjects, Peanut Allergies | Not applicable | Not yet recruiting | Laura Ozer Kettner | 56 | 2026-10-01 | 2026-10-26 |
| Oral Immunotherapy for Children With Egg Allergy Oral immunotherapy with egg - Egg Allergy, Egg Hypersensitivity | Not applicable | Not yet recruiting | Laura Ozer Kettner | 76 | 2026-10-01 | 2026-10-22 |
| Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care targeted therapy plus immunotherapy - Hepatocellular Carcinoma | Phase 2 | Recruiting | Anhui Provincial Hospital | 60 | 2026-09-16 | 2026-09-21 |
| Oral Immunotherapy for Children With Cow's Milk Allergy Oral immunotherapy with cow's milk - Milk Allergy, Cow's, Food Allergy in Children | Not applicable | Not yet recruiting | Laura Ozer Kettner | 56 | 2026-09-01 | 2026-08-17 |
| A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer standard EBRT+Brachytherapy, Cisplatin, Neoadjuvant chemoimmunotherapy - Locally Advanced Cervical Carcinoma | Phase 3 | Not yet recruiting | Fujian Cancer Hospital | 486 | 2026-09-01 | 2026-05-29 |
| TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study. TACE combined with thermal ablation, Targeted Therapy, Immunotherapy - Gastric Cancer With Liver Metastases | Phase 2 | Not yet recruiting | Shandong Provincial Hospital | 40 | 2026-08-01 | 2026-05-22 |
| Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC Short-course radiotherapy, Long-course radiotherapy, Immunotherapy - Locally Advanced Rectal Adenocarcinoma, Neoadjuvant Chemoradiation | Phase 2 / Phase 3 | Not yet recruiting | Beijing Friendship Hospital | 342 | 2026-07-15 | 2026-06-17 |
| TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC TACE (transarterial chemoembolization) combined with targeted/immunotherapy - Hepatocellular Carcinoma (HCC) | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 120 | 2026-07-01 | 2026-06-22 | |
| Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) Combination therapy with chemotherapy and immunotherapy, Surgery - ESCC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 200 | 2026-06-01 | 2026-05-13 |
| HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven) Procedure (FOLFOX-HAIC): Max 4 cycles within first 16 weeks., TACE (transarterial chemoembolization) combined with targeted/immunotherapy - Hepatocellular Carcinoma | Phase 3 | Recruiting | Binkui Li | 300 | 2026-05-15 | 2026-05-22 |
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
Showing 20 of 275. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (46) · Lung Neoplasms (20) · Carcinoma, Hepatocellular (19) · Melanoma (19) · Neoplasm Metastasis (16) · Neoplasms (13) · Esophageal Neoplasms (12) · Food Hypersensitivity (10) · Squamous Cell Carcinoma of Head and Neck (10) · Breast Neoplasms (9) · Colorectal Neoplasms (9) · Head and Neck Neoplasms (8) · Brain Neoplasms (6) · Carcinoma, Renal Cell (6) · Esophageal Squamous Cell Carcinoma (6)
H. Lee Moffitt Cancer Center and Research Institute (11) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (10) · Shanghai Chest Hospital (8) · Sun Yat-sen University (7) · West China Hospital (7) · Fudan University (6) · Zhejiang Cancer Hospital (5) · Tianjin Medical University Cancer Institute and Hospital (4) · Zhejiang University (4) · Anhui Provincial Hospital (3) · Laboratorios Leti, S.L. (3) · Laura Ozer Kettner (3) · McGill University Health Centre/Research Institute of the McGill University Health Centre (3) · Peking University First Hospital (3) · Sichuan University (3)
China (110) · United States (66) · France (14) · Canada (9) · Germany (9) · Italy (9) · Netherlands (9) · Spain (9) · Australia (6) · Switzerland (5) · Belgium (4) · Denmark (4) · Sweden (4) · United Kingdom (3) · India (2)
Laura O Kettner, MD, PhD (3) · Alberto Chiappori, M.D. (2) · Himanshu Nagar, M.D. (2) · Hui Liu, Professor (2) · Liangrong Shi, M.D. (2) · Ramakrishnan Madhusoodanan, PHD (2) · Wen Yu, M.D (2) · Wencheng Zhang, M.D. (2) · Xingchen Peng (2) · You Lu (2) · Abdul Naqash, MD (1) · Adam Ostrowski, MD (1) · Adriana Rossi, M.D. (1) · Aiwu Ruth He, MD PhD (1) · Alex Menzies (1)
PMID 37280366, PMID 17515386, PMID 19403881, PMID 19515503, PMID 19696440, PMID 20498394, PMID 20842054, PMID 21561347, PMID 21699798, PMID 22596235, PMID 22658128, PMID 22867890, PMID 23127803, PMID 23436068, PMID 23740935, PMID 23775348, PMID 24131140, PMID 24145345, PMID 24408046, PMID 24738612, PMID 25601342, PMID 25754329, PMID 25799953, PMID 26628467, PMID 27402526, PMID 27441744, PMID 27462163, PMID 27595835, PMID 27999018, PMID 28094262, PMID 28196771, PMID 28273722, PMID 28577836, PMID 28973074, PMID 29149611, PMID 29454091, PMID 29464535, PMID 29556198, PMID 29945993, PMID 29959141, PMID 30093664, PMID 30207593, PMID 30211003, PMID 30370356, PMID 30406032, PMID 30619280, PMID 30642458, PMID 30695671, PMID 30948807, PMID 30961445
P30CA012197 (2), 2023 (1), P30CA014089 (1), P30CA016672 (1), P30CA033572 (1), R01CA258997 (1), R01CA283603 (1), U10CA180868 (1)